Abbvie’s Aseptic Fill Finish Manufacturing

Abbvie’s Aseptic Fill Finish Manufacturing

Abbvie Contract Manufacturing has nearly 30 years of experience with aseptic fill finish and lyophilization of a broad range of biopharmaceuticals. Our fill & finish suite in Sligo, Ireland can be used for filling your bulk drug substance, and also as a stand-alone service offering. We ensure the processes used at Abbvie for the manufacturing of our client drug product batches follow EMA standards and FDA guidelines.

Abbvie Contract Manufacturing services cover Cell line development, Fermentation biotechnology, cGMP manufacturing, Process optimization, Analytical characterization, and Validation. We are your complete and best choice for contract manufacturing of therapeutic proteins, vaccines, and Live Microbial Products.

Excellent project management is an important and determining factor in the success of any project we embark on. Thus, dedicated project management is our top priority. We offer our customers added value with outstanding E. coli technologies that increase significantly in the bioprocess efficiency and so reduce the cost of goods.

Why Choose Abbvie  Fill Finish Manufacturing

AbbVie offers two convenient fill-finish options for parenteral drug products: prefilled syringe and vials. As a major pharmaceutical partner, we provide all important elements of delivering high-quality parenteral products for commercial and clinical needs.

AbbVie will leverage its know-how and proven quality, regulatory, and operational network to help you achieve your milestones through comprehensive development and manufacturing support for your vial and syringe drug product formulations.

Drug Fill-Finish Industry Growth

The CMO-based Fill-Finish industry has been growing at the same rate as overall biopharma manufacturing. The products validate the ongoing trend seen in bioprocessing of manufacturing being produced at a smaller scale, whether due to less product demand or higher yields.

Fill-finish is itself more mechanical and repetitive than other areas of biopharma manufacture, and innovations tend to be incremental, such as improved equipment performance. Fill-Finish stays very critical to biopharma manufacture. Its operations are mostly performed by CMOs, which dominate what has become a unique Fill-Finish CMO-based industry.

Innovative Technologies

We offer innovative technologies for the efficient and cost-effective production of biologics, also including plasma half-life extension, if desired. Enclosing Fill-Finish equipment with the use of isolator technology, in controlled environments, is a major ongoing trend.

CMOs are among the leaders in both the development and adoption of this and other new Fill-Finish technologies, so expect more innovations in this area to result from partnerships between the CMOs and their equipment suppliers.

Process Development

This is the link between research and the successive commercial production of biopharmaceuticals. Our goal is to develop a cost-effective and robust manufacturing process that can be validated and yield maximum quantities of high-quality products while observing all processes and product specifications.

Fill-Finish is not the most active area for biopharma innovations, but it operates at the point of highest product value. It advances risk reduction, product quality, and efficiency which will certainly bring improvements to this segment.

At Abbvie, we serve customers from different locations such as Germany, Ireland, Italy, the USA, and Puerto Rico. Our Bioprocess Development department focuses mainly on process development, material supply for preclinical trials, strain/analytical development, process transfer, and process characterization.